174 related articles for article (PubMed ID: 7605999)
1. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.
Bataille R; Barlogie B; Lu ZY; Rossi JF; Lavabre-Bertrand T; Beck T; Wijdenes J; Brochier J; Klein B
Blood; 1995 Jul; 86(2):685-91. PubMed ID: 7605999
[TBL] [Abstract][Full Text] [Related]
2. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract][Full Text] [Related]
3. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
Klein B; Wijdenes J; Zhang XG; Jourdan M; Boiron JM; Brochier J; Liautard J; Merlin M; Clement C; Morel-Fournier B
Blood; 1991 Sep; 78(5):1198-204. PubMed ID: 1715218
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
5. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
Legouffe E; Liautard J; Gaillard JP; Rossi JF; Wijdenes J; Bataille R; Klein B; Brochier J
Clin Exp Immunol; 1994 Nov; 98(2):323-9. PubMed ID: 7955540
[TBL] [Abstract][Full Text] [Related]
6. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
7. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.
Ozaki S; Kosaka M; Wakahara Y; Ozaki Y; Tsuchiya M; Koishihara Y; Goto T; Matsumoto T
Blood; 1999 Jun; 93(11):3922-30. PubMed ID: 10339501
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Lu ZY; Zhang XG; Rodriguez C; Wijdenes J; Gu ZJ; Morel-Fournier B; Harousseau JL; Bataille R; Rossi JF; Klein B
Blood; 1995 May; 85(9):2521-7. PubMed ID: 7727780
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
Urashima M; Chauhan D; Uchiyama H; Freeman GJ; Anderson KC
Blood; 1995 Apr; 85(7):1903-12. PubMed ID: 7535594
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF; Fegueux N; Lu ZY; Legouffe E; Exbrayat C; Bozonnat MC; Navarro R; Lopez E; Quittet P; Daures JP; Rouillé V; Kanouni T; Widjenes J; Klein B
Bone Marrow Transplant; 2005 Nov; 36(9):771-9. PubMed ID: 16113665
[TBL] [Abstract][Full Text] [Related]
11. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.
Shima Y; Nishimoto N; Ogata A; Fujii Y; Yoshizaki K; Kishimoto T
Blood; 1995 Feb; 85(3):757-64. PubMed ID: 7530506
[TBL] [Abstract][Full Text] [Related]
12. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
Uchiyama H; Barut BA; Mohrbacher AF; Chauhan D; Anderson KC
Blood; 1993 Dec; 82(12):3712-20. PubMed ID: 8260708
[TBL] [Abstract][Full Text] [Related]
13. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulating IL-6 activity by murine monoclonal antibodies.
Brochier J; Legouffe E; Liautard J; Gaillard JP; Mao LQ; Bataille R; Rossi JF; Klein B
Int J Immunopharmacol; 1995 Jan; 17(1):41-8. PubMed ID: 7782152
[TBL] [Abstract][Full Text] [Related]
15. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines.
Drexler HG; Meyer C; Gaidano G; Carbone A
Leukemia; 1999 Apr; 13(4):634-40. PubMed ID: 10214873
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.
Taetle R; Dos Santos B; Ohsugi Y; Koishihara Y; Yamada Y; Messner H; Dalton W
J Natl Cancer Inst; 1994 Mar; 86(6):450-5. PubMed ID: 8120920
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
19. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
